~ PEDMARK TM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARK TM ~ ~ Recently Announced Up to $45 Million in Funding from Petrichor to Support the Potential U.S.

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM   ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023  ~ ~ Funding to Support the Potential

RESEARCH TRIANGLE PARK, N.C. , June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual General Meeting of Shareholders were

RESEARCH TRIANGLE PARK, N.C. , May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM  (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARK TM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3 Million in Cash and $5 Million of

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ RESEARCH TRIANGLE PARK, N.C. , , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S.

RESEARCH TRIANGLE PARK, N.C. , March 25, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in

RESEARCH TRIANGLE PARK, N.C. , March 24, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™ (a unique

~ Resubmission of NDA for PEDMARK™  Targeted for the First Quarter of 2022  ~ ~ Company has Approximately $21.1 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc.

RESEARCH TRIANGLE PARK, N.C. , Jan. 31, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in